Yuchong Peng

1.0k total citations
38 papers, 730 citations indexed

About

Yuchong Peng is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Yuchong Peng has authored 38 papers receiving a total of 730 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 11 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Yuchong Peng's work include Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Ubiquitin and proteasome pathways (8 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers). Yuchong Peng is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Ubiquitin and proteasome pathways (8 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers). Yuchong Peng collaborates with scholars based in China, Brunei and Germany. Yuchong Peng's co-authors include Linglong Yin, Youhong Liu, Bowen Yuan, Qianling Zhu, Tuoyu Cao, Yingxue Gao, Xiaohui Yu, Xiong Li, Liang Ma and Xuegong Fan and has published in prestigious journals such as PLoS ONE, Oncogene and British Journal of Cancer.

In The Last Decade

Yuchong Peng

37 papers receiving 723 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuchong Peng China 14 398 218 192 147 125 38 730
Shunli Shen China 16 349 0.9× 187 0.9× 249 1.3× 179 1.2× 101 0.8× 32 689
Amanda Mikels‐Vigdal United States 10 254 0.6× 206 0.9× 174 0.9× 100 0.7× 109 0.9× 14 662
Chaohui Zuo China 17 422 1.1× 169 0.8× 273 1.4× 128 0.9× 123 1.0× 45 823
Imane El Dika United States 13 207 0.5× 214 1.0× 145 0.8× 178 1.2× 69 0.6× 30 573
Haosheng Jin China 16 420 1.1× 294 1.3× 342 1.8× 177 1.2× 106 0.8× 52 913
Yajin Chen China 15 550 1.4× 235 1.1× 340 1.8× 195 1.3× 99 0.8× 43 959
Guannan Tang China 14 407 1.0× 170 0.8× 366 1.9× 80 0.5× 136 1.1× 23 726
Bei‐Ge Jiang China 15 308 0.8× 135 0.6× 219 1.1× 111 0.8× 73 0.6× 27 650
Tameyoshi Yamamoto Japan 11 253 0.6× 253 1.2× 199 1.0× 264 1.8× 116 0.9× 30 675
Chetasi Talati United States 16 512 1.3× 247 1.1× 157 0.8× 68 0.5× 50 0.4× 78 1.1k

Countries citing papers authored by Yuchong Peng

Since Specialization
Citations

This map shows the geographic impact of Yuchong Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuchong Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuchong Peng more than expected).

Fields of papers citing papers by Yuchong Peng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuchong Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuchong Peng. The network helps show where Yuchong Peng may publish in the future.

Co-authorship network of co-authors of Yuchong Peng

This figure shows the co-authorship network connecting the top 25 collaborators of Yuchong Peng. A scholar is included among the top collaborators of Yuchong Peng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuchong Peng. Yuchong Peng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xu, Jing‐Xuan, Yuangang Su, Yuanyuan Chen, et al.. (2025). Immune infiltration landscape and potential drug-targeted implications for hepatocellular carcinoma with ‘progression/hyper-progression’ recurrence. Annals of Medicine. 57(1). 2456113–2456113. 2 indexed citations
2.
3.
Peng, Yuchong, Jingjing Huang, Youhong Liu, et al.. (2024). SKP2 inhibition activates tumor cell-intrinsic immunity by inducing DNA replication stress and genomic instability. British Journal of Cancer. 132(1). 81–92. 5 indexed citations
4.
Xu, Jing‐Xuan, Yuanyuan Chen, Lu‐Nan Qi, & Yuchong Peng. (2024). Investigation of the causal relationship between breast cancer and thyroid cancer: a set of two-sample bidirectional Mendelian randomization study. Endocrine. 87(1). 196–205. 1 indexed citations
5.
Xu, Jing‐Xuan, et al.. (2024). New evidence: Metformin unsuitable as routine adjuvant for breast cancer: a drug-target mendelian randomization analysis. BMC Cancer. 24(1). 691–691. 3 indexed citations
6.
Peng, Yuchong, Youhong Liu, Yubing Ye, et al.. (2023). PLK1 maintains DNA methylation and cell viability by regulating phosphorylation-dependent UHRF1 protein stability. Cell Death Discovery. 9(1). 367–367. 6 indexed citations
7.
Peng, Yuchong, Jing‐Xuan Xu, Xue‐Mei You, et al.. (2023). Specific gut microbiome signature predicts hepatitis B virus-related hepatocellular carcinoma patients with microvascular invasion. Annals of Medicine. 55(2). 2283160–2283160. 7 indexed citations
8.
9.
Cao, Tuoyu, Yubing Ye, Youhong Liu, et al.. (2023). AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer. Oncogenesis. 12(1). 1–1. 15 indexed citations
10.
Xu, Jing‐Xuan, et al.. (2022). Outcomes of postoperative adjuvant transarterial chemoembolization for hepatocellular carcinoma according to the Ki67 index. Future Oncology. 18(17). 2113–2125. 3 indexed citations
11.
Peng, Yuchong, et al.. (2022). Gut microbiome dysbiosis in patients with hepatitis B virus-related hepatocellular carcinoma after extended hepatectomy liver failure. Annals of Translational Medicine. 10(10). 549–549. 10 indexed citations
12.
13.
Peng, Yuchong, et al.. (2019). A meta-analysis of MDR1 polymorphisms rs1128503 and rs1045642 and susceptibility to hepatocellular carcinoma. Journal of International Medical Research. 47(7). 2800–2809. 4 indexed citations
14.
Yu, Xiaohui, Youhong Liu, Linglong Yin, et al.. (2018). Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition. Oncogene. 38(4). 549–563. 46 indexed citations
15.
Yin, Linglong, Youhong Liu, Yuchong Peng, et al.. (2018). PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells. Journal of Experimental & Clinical Cancer Research. 37(1). 153–153. 91 indexed citations
16.
Zhu, Qianling, Zheng Li, Yongbo Peng, et al.. (2017). The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells. Cell Death and Disease. 8(3). e2659–e2659. 100 indexed citations
17.
Wang, Yanyan, Ning‐Fu Peng, Yuchong Peng, et al.. (2016). Preoperative Ratio of Neutrophils to Lymphocytes Predicts Postresection Survival in Selected Patients With Early or Intermediate Stage Hepatocellular Carcinoma. Medicine. 95(5). e2722–e2722. 39 indexed citations
18.
Peng, Yuchong, Jian‐Hong Zhong, Zhibo Xie, et al.. (2016). Combination of 5-fluorouracil and 2-morphilino-8-phenyl-4H-chromen-4-one may inhibit liver cancer stem cell activity. Tumor Biology. 37(8). 10943–10958. 4 indexed citations
19.
Ye, Haihong, Jiazhou Ye, Zhibo Xie, et al.. (2016). Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein. World Journal of Gastroenterology. 22(13). 3632–3632. 12 indexed citations
20.
Xie, Zhibo, Xiaobo Wang, Yuchong Peng, et al.. (2014). Systematic review comparing the safety and efficacy of conventional and drug‐eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatology Research. 45(2). 190–200. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shunli Shen Breakdown of academic impact, for papers by Amanda Mikels‐Vigdal Breakdown of academic impact, for papers by Chaohui Zuo Breakdown of academic impact, for papers by Imane El Dika Breakdown of academic impact, for papers by Haosheng Jin Breakdown of academic impact, for papers by Yajin Chen Breakdown of academic impact, for papers by Guannan Tang Breakdown of academic impact, for papers by Bei‐Ge Jiang Breakdown of academic impact, for papers by Tameyoshi Yamamoto Breakdown of academic impact, for papers by Chetasi Talati
Rankless by CCL
2026